
TECX
Tectonic Therapeutic Inc.
$15.78
+$0.80(+5.34%)
50
Overall
--
Value
50
Tech
--
Quality
Market Cap
$299.58M
Volume
572.98K
52W Range
$13.70 - $61.07
Target Price
$79.75
Order:
Income Statement
Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||
Total Revenue | -- | -- | -- | -- | $23.0K | $77.0K | -- | ||
Total Revenue | -- | -- | -- | -- | $23.0K | $77.0K | -- | ||
COST OF GOODS SOLD | |||||||||
Cost of Revenue | -- | -- | -- | -- | $3.0M | -- | -- | ||
GROSS PROFIT | |||||||||
Gross Profit | -- | -- | -- | -- | $-2.9M | $-2.0M | -- | ||
OPERATING EXPENSES | |||||||||
Operating Expenses | $-46.2M | $75.8M | $120.2M | $118.8M | $105.4M | $44.6M | $58.0M | ||
Research & Development | $35.1M | $55.0M | $87.2M | $83.1M | $72.2M | $37.0M | $41.4M | ||
Research Expense | $35.1M | $55.0M | $87.2M | $83.1M | $72.2M | $37.0M | $41.4M | ||
Selling, General & Administrative | $11.1M | $20.8M | $33.0M | $35.7M | $33.2M | $7.7M | $16.7M | ||
General & Administrative Expenses | $11.1M | $20.8M | $33.0M | $35.7M | $33.2M | $7.7M | $16.7M | ||
Salaries & Wages | $-2.2M | $-6.8M | -- | -- | -- | $1.1M | $3.5M | ||
Depreciation & Amortization | $-380.0K | $-850.0K | $1.2M | $1.4M | $1.4M | $1.5M | $1.6M | ||
Depreciation & Amortization | $-380.0K | $-850.0K | $1.2M | $1.4M | $1.4M | $1.5M | $1.6M | ||
Amortization | -- | -- | -- | -- | -- | $488.0K | $448.0K | ||
Other Operating Expenses | -- | -- | -- | -- | $3.0M | $44.6M | $58.0M | ||
OPERATING INCOME | |||||||||
Operating income | $-46.2M | $-75.8M | $-120.2M | $-118.8M | $-105.4M | $-44.6M | $-58.0M | ||
EBITDA | $-45.9M | $-72.1M | $-119.0M | $-117.4M | $-104.0M | $-55.7M | $-73.2M | ||
NON-OPERATING ITEMS | |||||||||
Interest Expense (Non-Operating) | -- | -- | -- | $203.0K | $1.8M | $151.0K | $107.0K | ||
Intinc | $1.7M | $2.9M | $719.0K | -- | -- | $581.0K | $4.3M | ||
Net Non-Operating Interest Income/Expense | $1.7M | $2.9M | $719.0K | $-203.0K | $299.0K | $581.0K | $4.3M | ||
Gain on Sale of Securities | $-1.6M | -- | $719.0K | $-224.0K | $-299.0K | $2.4M | -- | ||
Other Income/Expense | $1.8M | $90.0K | $-516.0K | $285.0K | $-157.0K | $-396.0K | $511.0K | ||
Other Special Charges | $-215.0K | $-90.0K | $-203.0K | $-61.0K | $-157.0K | $396.0K | $-511.0K | ||
SPECIAL ITEMS | |||||||||
Restructring And Mn A Income | -- | -- | -- | -- | -- | $5.1M | -- | ||
Special Income Charges | -- | -- | -- | -- | -- | $-6.0M | -- | ||
Impairment of Capital Assets | -- | -- | -- | -- | -- | $940.0K | -- | ||
PRE-TAX INCOME | |||||||||
EBIT | $-46.4M | $-73.0M | $-120.2M | $-118.8M | $-105.4M | $-57.2M | $-74.8M | ||
Pre-Tax Income | $-46.4M | $-73.0M | $-119.7M | $-119.1M | $-105.9M | $-43.7M | $-54.3M | ||
INCOME TAX | |||||||||
Tax Provision | -- | -- | -- | -- | -- | $-14.6M | $-16.9M | ||
NET INCOME | |||||||||
Net Income | $-46.4M | $-73.0M | $-119.7M | $-119.1M | $-105.9M | $-42.8M | $-58.0M | ||
Net Income (Continuing Operations) | $-46.4M | $-73.0M | $-119.7M | $-119.1M | $-105.9M | $-42.8M | $-58.0M | ||
Net Income (Discontinued Operations) | $-46.4M | $-73.0M | $-119.7M | $-119.1M | $-105.9M | $-42.8M | $-58.0M | ||
Net Income (Common Stockholders) | $-48.6M | $-73.0M | $-119.7M | $-119.1M | $-105.9M | $-42.8M | $-58.0M | ||
Normalized Income | -- | -- | -- | -- | -- | -- | $-71.2M | ||
TOTALS | |||||||||
Total Expenses | $-46.2M | $75.8M | $120.2M | $118.8M | $105.4M | $44.6M | $58.0M | ||
SHARE & EPS DATA | |||||||||
Average Shares Outstanding | $1.1M | $27.4M | $36.2M | $42.9M | $43.7K | $3.7M | $8.5M | ||
Average Shares Outstanding (Diluted) | $1.1M | $27.4M | $36.2M | $42.9M | $43.7K | $3.7M | $8.5M | ||
Shares Outstanding | $2.0M | $36.0M | $41.6M | $43.7M | $18.7M | $3.7M | $18.7M | ||
Basic EPS | -- | -- | $-3.31 | $-2.78 | $-2.42 | $3.24 | $-6.83 | ||
Basic EPS (Continuing Operations) | -- | -- | $-3.31 | $-2.78 | $-2.42 | $3.24 | $-6.83 | ||
Diluted EPS | $-43.44 | $-2.66 | $-3.31 | $-2.78 | $-2.42 | $3.24 | $-6.83 | ||
Diluted EPS (Continuing Operations) | -- | $-2.66 | -- | -- | $-2.42 | $3.24 | $-6.83 | ||
OTHER METRICS | |||||||||
Accretion On Preferred Stock | $2.2M | -- | -- | -- | -- | -- | -- | ||
Gain On Sale Of P P E | -- | -- | -- | -- | -- | $83.7M | -- | ||
Other Gand A | $11.1M | $20.8M | $33.0M | $35.7M | $33.2M | $7.7M | $16.7M | ||
Other Impairment Of Capital Assets | $-235.0K | -- | -- | -- | -- | $-937.0K | -- | ||
Otherunder Preferred Stock Dividend | $2.2M | -- | -- | -- | -- | -- | -- | ||
Preferred Stock Dividends | $2.2M | -- | -- | -- | -- | -- | -- | ||
Rent And Landing Fees | $11.1M | $-2.3M | $2.4M | $2.6M | $3.2K | -- | -- | ||
Restruct | -- | -- | -- | -- | -- | $5.1M | -- |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | TECX | $15.78 | +5.3% | 572.98K |
3 | ||||
4 | ||||
5 | ||||
6 |
Get Tectonic Therapeutic Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW